Comment on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients:: cost-effectiveness analysis in the UK setting -: Reply

被引：0
|
作者：
Valentine, William J.
Palmer, Andrew J.
Lammert, Morten
Nicklasson, Lars
Foos, Volker
Roze, Stephane
机构：
[1] CORE, Ctr Outcomes Res, CH-4102 Binningen, Switzerland
[2] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[3] Novo Nordisk Inc, Princeton, NJ USA
来源：
CURRENT MEDICAL RESEARCH AND OPINION | 2006年 / 22卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：968 / 969
页数：2
相关论文
共 50 条
  • [1] Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients:: cost-effectiveness analysis in the UK setting
    Currie, CJ
    McEwan, P
    Poole, C
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 967 - 968
  • [2] Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting
    Valentine, WJ
    Palmer, AJ
    Lammert, M
    Nicklasson, L
    Foos, V
    Roze, S
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2005, 21 (12) : 2063 - 2071
  • [3] Treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naive type 2 diabetes patients: long-term effects on diabetesrelated complications
    Lammert, M
    Palmer, AJ
    Roze, S
    Valentine, WJ
    [J]. DIABETOLOGIA, 2005, 48 : A308 - A309
  • [4] SHORT AND LONG-TERM COST-EFFECTIVENESS OF STARTING BIPHASIC INSULIN ASPART 30 IN INSULIN-NAIVE PEOPLE WITH TYPE-2 DIABETES
    Home, P. D.
    Soewondo, P.
    Hussein, Z.
    Shafie, A. A.
    AlRaddady, K.
    Baadbad, R.
    Hammerby, E.
    Nikolajsen, A.
    Andersen, M. F. B.
    Henriksen, O.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A164 - A164
  • [5] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
    Kostyuk, A.
    Akanov, A.
    Almadiyeva, A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
  • [6] Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China
    James L. Palmer
    Amélie Beaudet
    Jeremy White
    Juliette Plun-Favreau
    Jayne Smith-Palmer
    [J]. Advances in Therapy, 2010, 27 : 814 - 827
  • [7] Cost-Effectiveness of Biphasic Insulin Aspart versus Insulin Glargine in Patients with Type 2 Diabetes in China
    Palmer, James L.
    Beaudet, Amelie
    White, Jeremy
    Plun-Favreau, Juliette
    Smith-Palmer, Jayne
    [J]. ADVANCES IN THERAPY, 2010, 27 (11) : 814 - 827
  • [8] Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes
    Cheng, Huafeng
    Wan, Xu
    Ma, Jing
    Wu, Bin
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (03) : 445 - 455
  • [9] An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naive people with poorly controlled type 2 diabetes
    Shafie, Asrul Akmal
    Gupta, Vishal
    Baabbad, Ranya
    Hammerby, Eva
    Home, Philip
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (02) : 319 - 327
  • [10] Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients With Type 2 Diabetes Mellitus
    Brown, Stephen T.
    Grima, Daniel Grima
    Sauriol, Luc
    [J]. CLINICAL THERAPEUTICS, 2014, 36 (11) : 1576 - 1587
12345